305 related articles for article (PubMed ID: 31219586)
1. Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study.
Chiloiro S; Bima C; Tartaglione T; Giampietro A; Gessi M; Lauretti L; Anile C; Colosimo C; Rindi G; Pontecorvi A; De Marinis L; Bianchi A
J Clin Endocrinol Metab; 2019 Nov; 104(11):5478-5482. PubMed ID: 31219586
[TBL] [Abstract][Full Text] [Related]
2. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.
Chiloiro S; Giampietro A; Mirra F; Donfrancesco F; Tartaglione T; Mattogno PP; Angelini F; Liverana L; Gessi M; Carmelo A; Rindi G; Giustina A; Fleseriu M; Pontecorvi A; De Marinis L; Bianchi A
Eur J Endocrinol; 2021 Feb; 184(2):217-229. PubMed ID: 33136550
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.
Ciresi A; Radellini S; Guarnotta V; Giordano C
BMC Endocr Disord; 2018 Jan; 18(1):2. PubMed ID: 29361932
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
[TBL] [Abstract][Full Text] [Related]
5. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly.
Coopmans EC; Schneiders JJ; El-Sayed N; Erler NS; Hofland LJ; van der Lely AJ; Petrossians P; Potorac J; Muhammad A; Neggers SJCMM
Eur J Endocrinol; 2020 Jun; 182(6):595-605. PubMed ID: 32375119
[TBL] [Abstract][Full Text] [Related]
6. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs.
Araujo-Castro M; Biagetti B; Menéndez Torre E; Novoa-Testa I; Cordido F; Pascual-Corrales E; Rodríguez Berrocal V; Guerrero-Pérez F; Vicente A; Percovich Hualpa JC; García-Centeno R; González-Fernández L; Ollero García MD; Irigaray Echarri A; Moure Rodríguez MD; Novo-Rodríguez C; Calatayud M; Villar-Taibo R; Bernabéu I; Alvarez-Escola C; Benítez Valderrama P; Tenorio-Jiménez C; Abellán Galiana P; Venegas E; González-Molero I; Iglesias P; Blanco-Carrera C; Vidal-Ostos De Lara F; de Miguel Novoa P; López Mezquita E; Hanzu FA; Aldecoa I; Aznar S; Lamas C; Aulinas A; Asla Q; Gracia Gimeno P; Recio Córdova JM; Avilés-Pérez MD; Asensio-Wandosell D; Sampedro-Núñez M; Cámara R; Paja Fano M; Ruz-Caracuel I; Fajardo C; Marazuela M; Puig-Domingo M
Endocr Relat Cancer; 2024 Jul; 31(7):. PubMed ID: 38713182
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study.
Colao A; Zgliczyński W; Komorowski J; Kos-Kudła B; Tabarin A; Kerlan V; Minuto FM; Scaroni C; Bolanowski M
Endokrynol Pol; 2019; 70(4):305-312. PubMed ID: 31274183
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain.
Peral C; Cordido F; Gimeno-Ballester V; Mir N; Sánchez-Cenizo L; Rubio-Rodríguez D; Rubio-Terrés C
Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):105-114. PubMed ID: 31055976
[No Abstract] [Full Text] [Related]
9. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).
Muhammad A; van der Lely AJ; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; Neggers SJCMM
J Clin Endocrinol Metab; 2018 Feb; 103(2):586-595. PubMed ID: 29155991
[TBL] [Abstract][Full Text] [Related]
10. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.
Iacovazzo D; Carlsen E; Lugli F; Chiloiro S; Piacentini S; Bianchi A; Giampietro A; Mormando M; Clear AJ; Doglietto F; Anile C; Maira G; Lauriola L; Rindi G; Roncaroli F; Pontecorvi A; Korbonits M; De Marinis L
Eur J Endocrinol; 2016 Feb; 174(2):241-50. PubMed ID: 26586796
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
13. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression.
Muhammad A; Coopmans EC; Gatto F; Franck SE; Janssen JAMJL; van der Lely AJ; Hofland LJ; Neggers SJCMM
J Clin Endocrinol Metab; 2019 Mar; 104(3):915-924. PubMed ID: 30346538
[TBL] [Abstract][Full Text] [Related]
14. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
[TBL] [Abstract][Full Text] [Related]
15. How to Position Pasireotide LAR Treatment in Acromegaly.
Coopmans EC; Muhammad A; van der Lely AJ; Janssen JAMJL; Neggers SJCMM
J Clin Endocrinol Metab; 2019 Jun; 104(6):1978-1988. PubMed ID: 30608534
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with somatostatin analogues and pegvisomant in acromegaly.
Neggers SJ; van der Lely AJ
Growth Horm IGF Res; 2011 Jun; 21(3):129-33. PubMed ID: 21498099
[TBL] [Abstract][Full Text] [Related]
17. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
18. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone.
van der Lely AJ; Bernabeu I; Cap J; Caron P; Colao A; Marek J; Neggers S; Birman P
Eur J Endocrinol; 2011 Mar; 164(3):325-33. PubMed ID: 21148630
[TBL] [Abstract][Full Text] [Related]
19. Second line treatment of acromegaly: Pasireotide or Pegvisomant?
Chiloiro S; Bianchi A; Giampietro A; Pontecorvi A; Raverot G; Marinis L
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101684. PubMed ID: 35931640
[TBL] [Abstract][Full Text] [Related]
20. [Epidemiology of acromegaly in Spain].
Sesmilo G
Endocrinol Nutr; 2013 Oct; 60(8):470-4. PubMed ID: 23246411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
